Zydus Wellness News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Zydus Wellness Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Zydus Wellness Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Zydus Wellness from all sources in a single place.

Zydus Wellness Ltd.

01 Jan 2026

461.00

-2.70%

Company Update

Zydus Wellness Ltd-$ - 531335 - Clarification sought from Zydus Wellness Ltd

BSE India

The Exchange has sought clarification from Zydus Wellness Ltd on January 1, 2026, with reference to Movement in Volume.The reply is awaited.

Zydus Wellness Ltd.

01 Jan 2026

461.00

-2.70%

Company Update

Zydus Wellness Ltd-$ - 531335 - Clarification On Volume Movement

BSE India

Clarification on volume movement

pdf

Zydus Wellness Ltd.

31 Dec 2025

461.00

-2.70%

Zydus Wellness zooms 10% in trade; Motilal Oswal initiates 'Buy'; check TP

Business Standard

Motilal Oswal Financial Services has initiated coverage on Zydus Wellness with 'Buy' for a target of 575, which implies an upside of 25.8 per cent from current levels

Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.

Zydus Wellness Has Attractive Risk-Reward Profile, Says Motilal Oswal On 'Buy' Initiation Check Details

NDTV Profit | 31 Dec 2025

Zydus Wellness Ltd.

31 Dec 2025

461.00

-2.70%

Scaling up the wellness brand equity

Buy: Zydus Wellness Ltd.

Motilal Oswal

Zydus Wellness is a diversified health and nutrition company (~INR40bn revenue) with leadership in several consumer wellness categories. The company’s core portfolio consists of sugar substitutes (Sugar Free), glucose powders (Glucon-D), skincare (Everyuth), functional foods (Nutralite), prickly-heat powder (Nycil), and nutritional beverages (Complan).

Zydus Wellness Ltd. is trading above all available SMAs

Zydus Wellness Ltd.

27 Dec 2025

461.00

-2.70%

Company Update

Zydus Wellness Ltd-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication for opening of special window for re-lodgement of transfer requests of physical shares

pdf

Zydus Wellness Ltd.

26 Dec 2025

461.00

-2.70%

SAST

Zydus Wellness Ltd-$ - 531335 - Closure of Trading Window

BSE India

Trading window closure

pdf

Zydus Wellness Ltd.

19 Dec 2025

461.00

-2.70%

Zydus Wellness rallied on the Comfort Click deal. Has the excitement faded?

livemint

After acquiring UK-based Comfort Click for 2,380 crore, Zydus' stock surged. The move expands its global wellness footprint, but near-term profitability pressures remain.

Zydus Wellness Ltd. is trading above all available SMAs

Zydus Wellness Ltd.

15 Dec 2025

461.00

-2.70%

Zydus Life's US arm gets FDA nod for Menkes disease drug resubmission

Business Standard

The drug, CUTX-101, is intended for the treatment of Menkes disease, a rare X-linked recessive genetic disorder affecting male children

Zydus Wellness Ltd. is trading above all available SMAs

Zydus Wellness Ltd.

10 Dec 2025

461.00

-2.70%

Zydus Lifesciences introduces biosimilar for cancer patients' bone health

Business Standard

Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours, the Ahmedabad-based drug firm said in a regulatory filing. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. The company said it has priced 'Zyrifa' at MRP of Rs 12,495. Sharvil P Patel, Managing Director, Zydus Lifesciences Ltd said that with Denosumab 120 mg SC, the company aims to bring access, affordability of medication in cancer patients...